Kenneth Holt - Rockwell Medical Independent Director

RMTI Stock  USD 1.64  0.01  0.61%   

Director

Mr. Kenneth L. Holt is an Independent Director of Rockwell Medical Inc since March 2000 since 2000.
Age 61
Tenure 24 years
Address 30142 South Wixom road, Wixom, MI, United States, 48393
Phone248 960 9009
Webhttps://www.rockwellmed.com
Holt has over 25 years of experience in the dialysis industry., Since 1986, Mr. Holt, as an owner, was instrumental in the development, management and operation of several outpatient clinics in North Carolina, South Carolina and Georgia. Since 2001, he was an owner and managing partner of two firms that provide inpatient acute dialysis services to hospitals; Southeast Acute Services, LLC and Southern Renal Administrators. Among the outpatient facilities mentioned above, he was a founder and coowner of Charleston Renal Care, LLC, a kidney disease management company specializing in the treatment of endstage renal disease, until its sale in 2005. He was a founder and coowner of Savannah Dialysis Specialists, LLC, a disease management company specializing in the treatment of endstage renal disease, and served as the Managing Partner from October 1999 until its sale in 2004. From 1996 to October 1999, Mr. Holt served as Vice President for Gambro Healthcare, Inc

Rockwell Medical Management Efficiency

The company has return on total asset (ROA) of (0.0844) % which means that it has lost $0.0844 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4768) %, meaning that it created substantial loss on money invested by shareholders. Rockwell Medical's management efficiency ratios could be used to measure how well Rockwell Medical manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Capital Employed is estimated to decrease to -0.2. The current Return On Assets is estimated to decrease to -0.17. As of now, Rockwell Medical's Total Current Assets are increasing as compared to previous years. The Rockwell Medical's current Intangible Assets is estimated to increase to about 13 M, while Total Assets are projected to decrease to under 37.3 M.
The company currently holds 13.44 M in liabilities with Debt to Equity (D/E) ratio of 1.38, which is about average as compared to similar companies. Rockwell Medical has a current ratio of 2.15, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Rockwell Medical until it has trouble settling it off, either with new capital or with free cash flow. So, Rockwell Medical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Rockwell Medical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Rockwell to invest in growth at high rates of return. When we think about Rockwell Medical's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Ronald KennedyPetIQ Inc
71
Gerald GoldbergFSD Pharma Class
70
David UrbanFSD Pharma Class
N/A
Mark FirstPetIQ Inc
53
James ClarkePetIQ Inc
45
Yoseph BornsteinMicrobot Medical
65
Antaine FurlongFSD Pharma Class
40
Gary MichaelPetIQ Inc
77
Larry BirdPetIQ Inc
63
Scott BurellMicrobot Medical
52
Martin MaddenMicrobot Medical
57
Will SantanaPetIQ Inc
45
Jun ZhengChina SXT Pharmaceuticals
46
Moshe ShohamMicrobot Medical
64
Donal CarrollFSD Pharma Class
42
Alfred LimEUDA Health Holdings
72
Susan SholtisPetIQ Inc
51
Solomon MayerMicrobot Medical
62
Scott HuffPetIQ Inc
46
Vladimir KlacarFSD Pharma Class
N/A
Prattipati LaxminarainMicrobot Medical
59
Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan. Rockwell Medical operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 300 people. Rockwell Medical (RMTI) is traded on NASDAQ Exchange in USA. It is located in 30142 South Wixom road, Wixom, MI, United States, 48393 and employs 237 people. Rockwell Medical is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Rockwell Medical Leadership Team

Elected by the shareholders, the Rockwell Medical's board of directors comprises two types of representatives: Rockwell Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rockwell. The board's role is to monitor Rockwell Medical's management team and ensure that shareholders' interests are well served. Rockwell Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rockwell Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
John Cooper, Director
David Domzalski, Director
Angus Smith, Principal Financial Officer
Thomas Klema, CFO, Vice President Treasurer, Secretary
Mark Strobeck, CEO President
Marc MD, Chief Officer
James McCarthy, Senior Development
Timothy Chole, Senior Marketing
Mark Ravich, Director
Michael DeYoung, Vice President - Operations
Kenneth Holt, Independent Director
Benjamin Wolin, Chairman of the Board
Paul McGarry, Principal Accounting Officer, Vice President Corporate Controller
Megan Timmins, Chief VP
Patrick Bagley, Independent Director
David Kull, Principal Accounting Officer
Jim McCarthy, Senior Vice President - Corporate and Business Development
Jason Finkelstein, Investor Representative
Ajay Gupta, Chief Scientific Officer
Ronald Boyd, Independent Director
Lisa Colleran, Director
Jesse Neri, Senior Finance
Charlie Shiner, Vice President of Marketing
Raymond Pratt, Chief Medical Officer
Robin Smith, Director
Robert Chioini, Founder, Chairman of The Board and CEO
Heather Hunter, Senior Officer
Michael Rice, Co-Founder, LifeSci Advisors, LLC
Stuart Paul, CEO, Director

Rockwell Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rockwell Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

When determining whether Rockwell Medical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Rockwell Medical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Rockwell Medical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Rockwell Medical Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rockwell Medical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
For more detail on how to invest in Rockwell Stock please use our How to Invest in Rockwell Medical guide.
You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.

Complementary Tools for Rockwell Stock analysis

When running Rockwell Medical's price analysis, check to measure Rockwell Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rockwell Medical is operating at the current time. Most of Rockwell Medical's value examination focuses on studying past and present price action to predict the probability of Rockwell Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rockwell Medical's price. Additionally, you may evaluate how the addition of Rockwell Medical to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Is Rockwell Medical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rockwell Medical. If investors know Rockwell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rockwell Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.37)
Revenue Per Share
3.585
Quarterly Revenue Growth
0.144
Return On Assets
(0.08)
Return On Equity
(0.48)
The market value of Rockwell Medical is measured differently than its book value, which is the value of Rockwell that is recorded on the company's balance sheet. Investors also form their own opinion of Rockwell Medical's value that differs from its market value or its book value, called intrinsic value, which is Rockwell Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rockwell Medical's market value can be influenced by many factors that don't directly affect Rockwell Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rockwell Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Rockwell Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rockwell Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.